MedTrace Logo

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

NCT04647110 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 549

Last updated 2023-04-06

Study results available
· View outcomes & findings →

Summary

This study aims to explore for the first time how the different ALK TKIs have been sequenced in real-world clinical practice and with which outcomes for Swedish lung cancer patients

Conditions

  • ALK-positive NSCLC

Interventions

DRUG

crizotinib

as provided in real world practice

DRUG

alectinib

as provided in real world practice

DRUG

brigatinib

as provided in real world practice

DRUG

ceritinib

as provided in real world practice

DRUG

lorlatinib

as provided in real world practice

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-14
Primary Completion
2021-03-15
Completion
2021-03-15
FDA Drug
Yes

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04647110 on ClinicalTrials.gov